Engitix
Engitix is a London-based biotechnology company that partners with pharmaceutical companies to discover and validate ECM-targeted therapeutics for fibrosis, inflammation, and solid tumours using its proprietary human extracellular matrix drug discovery platform and bioinformatics data assets.
- Company typePrivate
- Founded2016
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Engitix does
Engitix is a London-based biotechnology company founded in 2016 as a spin-out of University College London's Institute for Liver and Digestive Health, developing a proprietary human extracellular matrix (ECM) drug discovery platform for fibrosis, inflammation, and solid tumours. The platform combines tissue- and disease-specific human ECM scaffolds, a 3D phenotypic screening capability, and the Engitomix bioinformatics platform — built on one of the world's largest proprietary human ECM datasets integrating mass-spectrometry, RNA-sequencing, imaging, and clinical metadata with AI/ML-driven analytics. Engitix holds an exclusive license from UCLB to foundational ECM decellularization patents invented by co-founder Dr Giuseppe Mazza.
The company operates a B2B partnership model, monetizing its platform through multi-year, multi-programme collaborations with pharmaceutical and biotechnology companies. Partnerships with Takeda (up to $500M for advanced fibrotic liver diseases plus up to $300M for fibrostenotic IBD), GSK (£44.5M upfront plus up to £118M per target in milestones for liver fibrosis regression), Dompè farmaceutici (Exscalate AI integration plus equity), and Morphic Therapeutic (fibrostenotic IBD) generate upfront fees, near-term payments tied to target validation, preclinical/development/regulatory/commercial milestones, and royalties on commercialized products. Engitix retains full control over its assets in these collaborations.
In parallel, Engitix has built an internal proprietary pipeline of discovery-stage assets — EGTX003 (inflammation/fibrosis), EGTX004 (solid tumours and advanced fibrosis), and EGTX006 (advanced fibrosis) — financed through approximately $79M of disclosed venture funding, led by Netherton Investments (Mike Platt/BlueCrest Capital) with Dompè as co-lead of the 2022 Series A. Headcount has grown to approximately 60-80 staff across London headquarters (WestWorks, White City Place) and a Cambridge, MA US subsidiary, supported by ISO 27001 certification and an expanding leadership team drawn from J&J, Novartis, Roche, GSK, and other major pharma organizations.
Engitix firmographics
Firmographics- Name
- Engitix
- Legal name
- ENGITIX LIMITED
- Website
- https://engitix.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Engitix is a London-based biotechnology company that partners with pharmaceutical companies to discover and validate ECM-targeted therapeutics for fibrosis, inflammation, and solid tumours using its proprietary human extracellular matrix drug discovery platform and bioinformatics data assets.
- Ownership category
- akta.pro rank
Engitix industry classification
Industry- Product category
- Biopharmaceutical Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Engitix is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Engitix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Partnership and Licensing Revenue: Engitix generates revenue through strategic partnerships with pharmaceutical companies. Partners pay upfront fees, near-term payments for target validation, and milestone payments tied to preclinical, development, regulatory, and commercial achievements. Royalties are received on sales of commercialized products.
- Platform Technology Access Fees: Partners receive access to ECM platform capabilities, facilities, and expertise in exchange for fees and milestone considerations. Dompé partnership included direct access to facilities, resources, and Exscalate AI drug discovery platform.
- Research Collaboration Payments: Funding for specific research collaboration activities including target identification, validation, and preclinical development. GSK deal included £44.5M upfront plus up to £118M per target in milestone payments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Takeda partnership deal valued at up to $500 million in milestones plus royalties |
| Other | Multi-year contract | Takeda IBD expansion deal valued at up to $300 million in milestones plus royalties |
| Other | Multi-year contract | GSK collaboration deal worth up to £44.5M upfront plus £118M per target in milestone payments plus royalties |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Engitix product offering
Product offeringCore offering
Engitix develops and applies a proprietary human extracellular matrix (ECM) drug discovery platform that uses tissue- and disease-specific human ECM scaffolds, the Engitomix bioinformatics platform, 3D-ECM bioassays, and a patient biosample archive to identify and validate novel therapeutic targets and biomarkers in fibrosis, inflammation, and solid tumours. The company offers its platform to pharmaceutical partners via licensing and research collaboration agreements and also advances its own internal pipeline of ECM-targeted therapeutic candidates.
Product overview
Engitix is a biopharmaceutical company built around its proprietary human extracellular matrix (ECM) drug discovery platform. The platform consists of tissue- and disease-specific human ECM scaffolds (the 3D ECM Bioassays), the Engitomix Bioinformatics Platform for multi-omics data integration and AI/ML-driven analytics, and an extensive bioarchive. This core technology drives both proprietary pipeline assets (EGTX004, EGTX003, EGTX006 targeting solid tumours, inflammation, and fibrosis) and partnered drug discovery programmes with Takeda (advanced liver diseases, IBD) and GSK (liver fibrosis regression).
Differentiator
Problem solved
Functional benefit
Products and services
- ECM Platform (Human Extracellular Matrix Platform)
Quantifiable outcome
- Takeda deal worth more than $500M including upfront, milestones, and royalties for advanced fibrotic liver diseases
- +4 more outcomes
Companies that use Engitix
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Engitix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Engitix partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- GSKcoreStrategic research collaboration and option agreement to identify and validate novel therapeutic targets for liver fibrosis regression. Engitix will use its proprietary human ECM Platform and multi-omics datasets to identify high-confidence targets. GSK will pay £44.5M upfront and near-term payments, up to £118M per target in milestone payments, plus tiered low-single digit royalties. GSK holds option to license resulting assays, datasets, and targets and lead further R&D and commercialization.
- Takeda Pharmaceuticals (IBD Expansion)coreExpanded collaboration to include discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Deal worth up to approximately $300M including upfront, milestone, and royalty payments. Builds on existing liver disease collaboration.
- Dompé farmaceuticicoreMulti-year, multi-programme strategic R&D collaboration combined with Series A co-investment. Dompé provides access to its Exscalate AI supercomputing structure-based drug design platform, facilities, and expertise. Deal includes equity investment and milestones. Engitix retains full control over assets and programmes. Dompé eligible for clinical and commercial milestones and royalties.
- Takeda PharmaceuticalscoreCollaboration and licensing agreement to discover and develop novel therapeutics for advanced fibrotic liver diseases including NASH. Engitix receives upfront payment, near-term payments for target validation, and is eligible for more than $500M in preclinical, development, regulatory, and commercial milestones, plus royalties. Takeda receives exclusive rights to develop and commercialize clinical candidates.
- Morphic TherapeuticminorResearch collaboration to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease (IBD), affecting approximately 30% of Crohn's Disease patients. Engitix applies its ECM platform to identify and characterize target expression, including integrin and non-integrin expression. Collaboration successfully established disease-specific human fibrostenotic ECM platform for target ID.
Scale indicators8 records
Recent moves10 records
Expansion highlights6 records
Engitix competitors and assessment
Company assessmentDirect peers
- Pliant Therapeutics: Clinical-stage biotech developing therapies for fibrotic diseases, including integrin-targeting candidates. Pliant's scientific advisor Scott Turner was former CSO there, indicating direct overlap in fibrosis biology and integrin-based therapeutic approaches overlapping with Engitix's ECM-derived integrin targets.
- Morphic Therapeutic: Biotech developing oral integrin therapies for fibrostenotic inflammatory bowel disease. Morphic is also a partner of Engitix for ECM-related target identification, representing direct overlap in integrin biology and fibrostenotic IBD as a therapeutic area.
Broad incumbents
- FibroGen: Established late-stage biotech with fibrosis-focused pipeline including pamrevlumab. Operates broadly in fibrotic disease drug development with multiple programmes across organs, overlapping with Engitix's fibrosis focus but at a more advanced clinical stage.
- Galapagos NV: Mid-cap biotech with historical fibrosis and inflammation programmes (e.g., ziritaxestat) and a cell therapy platform. Operates broadly in adjacent therapeutic areas to Engitix, including inflammation and fibrotic diseases.
Emerging players
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Recursion's platform-based discovery approach parallels Engitix's Engitomix bioinformatics platform, though Recursion operates across many therapeutic areas beyond fibrosis.
- Exscientia: AI-native drug discovery company using its Centaur platform for target identification and design. Dompè (an Engitix partner) leverages its own Exscalate platform, indicating a shared ecosystem of AI-augmented drug discovery comparable to Engitix's approach.
- Schrödinger, Inc. Computational drug discovery platform combining physics-based simulation with ML. Operates a platform-plus-pipeline model with pharma collaborations, comparable to Engitix's hybrid platform/partnership strategy, though broader in scope.
- Insitro: ML-driven drug discovery company combining high-throughput biology and patient-derived data. Insitro's approach of using patient-relevant data to discover targets parallels Engitix's patient-centric ECM platform, though Insitro operates across multiple therapeutic areas.
Regional players
- Redx Pharma: UK-based clinical-stage biotech with fibrosis and oncology programmes. Operates in similar therapeutic areas to Engitix (fibrosis, cancer) but is regionally focused on UK and targets small molecule discovery rather than ECM biology.
Others
- Vivet Therapeutics: Gene therapy company focused on liver diseases including metabolic disorders and Wilson disease. Eduardo Bravo (Engitix's Chairman) is also Chairman at Vivet, indicating an overlapping board-level connection and similar focus on liver-directed therapeutics.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Engitix social profiles
Digital presenceEngitix compliance and trust
Trust signalCompliance1 record
Engitix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Engitix leadership team
Management profileNumber of profiles
Profiles11 records
Engitix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Engitix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Engitix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Engitix
What does Engitix do?
Engitix develops and applies a proprietary human extracellular matrix (ECM) drug discovery platform that uses tissue- and disease-specific human ECM scaffolds, the Engitomix bioinformatics platform, 3D-ECM bioassays, and a patient biosample archive to identify and validate novel therapeutic targets and biomarkers in fibrosis, inflammation, and solid tumours. The company offers its platform to pharmaceutical partners via licensing and research collaboration agreements and also advances its own internal pipeline of ECM-targeted therapeutic candidates.
Is Engitix a public or private company?
Engitix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Engitix founded?
Engitix was founded in 2016. It employs 51 to 100 people.
Where is Engitix based?
Engitix is headquartered in London, United Kingdom, in the Europe region.
How does Engitix make money?
Three revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are platform Technology Access Fees and research Collaboration Payments.
Who are Engitix's main competitors?
Direct peers on record are Pliant Therapeutics and Morphic Therapeutic. Broad incumbents are FibroGen and Galapagos NV. Emerging players are Recursion Pharmaceuticals, Exscientia, Schrödinger, Inc. and Insitro. Redx Pharma is listed as a regional player. Vivet Therapeutics is listed as an others.
Does Engitix have an API?
No public API is recorded for Engitix.
What industry is Engitix in?
Engitix's product category is Biopharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.